Skip to main content

News

Recent News

February 12, 2026
ImmuneSensor Therapeutics Doses First Patient with Aicardi Goutières Syndrome (AGS) in Phase 1b Clinical Study of cGAS inhibitor, IMSB301

November 20, 2024
ImmuneSensor Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for cGAS Inhibitor Drug Candidate, IMSB301, for the Treatment of Aicardi Goutières Syndrome (AGS)

October 8, 2024
ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead cGAS Inhibitor Drug Candidate, IMSB301

In the News

September 19, 2024
Zhijian “James” Chen, Ph.D., UT Southwestern Medical Center, has been awarded the 2024 Albert Lasker Basic Medical Research Award for the discovery of the cGAS enzyme that senses foreign and self DNA, solving the mystery of how DNA stimulates immune and inflammatory responses.

September 19, 2024
DNA-Sensing Enzyme Wins the 2024 Lasker Award

September 19, 2024
Dallas scientist wins presetigious Lasker Award for immune research

September 19, 2024
Dallas scientist wins presetigious Lasker Award for immune research (video)

September 19, 2024
Zhijian “James” Chen Receives 2024 Albert Lasker Basic Medical Research Award

September 20, 2024
UT Southwestern biochemist Zhijian ‘James’ Chen, Ph.D., earns prestigious Lasker Award